Loading...
Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Jason Matthew Shohet MD, PhD

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Shohet, Jason

PropertyValue
keywords MYCN
overview

As a pediatric oncologist, my research goals are to develop more effective and less toxic therapies for childhood cancers with a special focus on neuroblastoma. This MYCN-driven malignancy of the peripheral sympathetic nervous system accounts for 13% of all pediatric cancer deaths. I have recently relocated to assume the position as Division Chief for Pediatric Hematology/Oncology at University of Massachusetts Medical School in Worcester, Ma. This is after 19 years as co-chair of the Neuroblastoma Research program at Texas Children’s Cancer Center, Baylor College of Medicine. The UMass Medical School and UMass Memorial Clinical organizations provides exceptional support and research infrastructure for basic and translational efforts. I am an affiliated member of the Cancer Biology program, the MD, PhD program and the division of Molecular, Cell and Cancer Biology (MCCB). 

A major focus of my laboratory is characterizing the role of MYCN in neuroblastoma pathogenesis and tumor stem cell biology. We have defined a novel tumor subpopulation meeting criteria as cancer stem cells or tumor initiating cells. That is the ability to self-renew, differentiate and recapitulate all the subsets of cells making up a complex tumor in vivo. We are further characterizing intra-tumor heterogeneity using single cell approaches.  

As part of this work we have characterized multiple direct transcriptional targets of MYCN which are either destabilize p53 (e.g. MDM2) or alter transcriptional pathways to promote proliferation and inhibit apoptosis (e.g. MCM7 or mir-34a). This work has involved developing novel transgenic mouse models, optimized orthotopic xenografts and conditional cell lines for gain and loss of function studies of both microRNAs and coding genes. Our most recent efforts resulted in defining a novel direct binding interaction of MYCN with p53 that reveals a novel oncogenic function for MYCN as a direct transcriptional cofactor for p53.


One or more keywords matched the following items that are connected to Shohet, Jason

Item TypeName
Academic Article MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
Academic Article MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Academic Article Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Academic Article Redefining functional MYCN gene signatures in neuroblastoma.
Academic Article MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.
Academic Article Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
Academic Article Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis.
Academic Article MDM2 as a critical effector of the MYCN oncogene in tumorigenesis.
Academic Article MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
Academic Article Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
Academic Article MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Academic Article A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Academic Article The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Academic Article Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Search Criteria
  • MYCN